430 related articles for article (PubMed ID: 8284686)
1. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma.
Figlin RA; Pierce WC; Belldegrun A
Semin Oncol; 1993 Dec; 20(6 Suppl 9):11-5. PubMed ID: 8284686
[No Abstract] [Full Text] [Related]
2. Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells.
Thompson JA; Benyunes MC; Bianco JA; Fefer A
Semin Oncol; 1993 Dec; 20(6 Suppl 9):46-51. PubMed ID: 8284692
[No Abstract] [Full Text] [Related]
3. European studies of interleukin-2 in metastatic renal cell carcinoma.
Atzpodien J; Kirchner H; Hänninen EL; Körfer A; Fenner M; Menzel T; Deckert M; Franzke A; Jonas U; Poliwoda H
Semin Oncol; 1993 Dec; 20(6 Suppl 9):22-6. PubMed ID: 8284688
[No Abstract] [Full Text] [Related]
4. Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma.
Legha SS; Buzaid AC
Semin Oncol; 1993 Dec; 20(6 Suppl 9):27-32. PubMed ID: 8054006
[No Abstract] [Full Text] [Related]
5. Adoptive immunotherapy of renal cell carcinoma: studies from the Surgery Branch, National Cancer Institute.
Linehan WM; Walther MM; Alexander RB; Rosenberg SA
Semin Urol; 1993 Feb; 11(1):41-3. PubMed ID: 8465127
[No Abstract] [Full Text] [Related]
6. Cellular therapy: scientific rationale and clinical results in the treatment of metastatic renal-cell carcinoma.
Pierce WC; Belldegrun A; Figlin RA
Semin Oncol; 1995 Feb; 22(1):74-80. PubMed ID: 7855622
[No Abstract] [Full Text] [Related]
7. Interferon-alpha and interleukin-2 in the treatment of renal cell cancer.
Holdener EE; Emmons RP; Brunda M; Evans L; Levitt D
Prog Clin Biol Res; 1990; 348():61-9. PubMed ID: 2201034
[No Abstract] [Full Text] [Related]
8. Pretreatment natural killer antigen density correlates to clinical response in tumor patients receiving long-term subcutaneous recombinant interleukin-2 and recombinant interferon-alpha.
Duensing S; Hadam M; Körfer A; Schomburg A; Menzel T; Grosse J; Kirchner H; Poliwoda H; Atzpodien J
Mol Biother; 1992 Dec; 4(4):170-3. PubMed ID: 1282326
[TBL] [Abstract][Full Text] [Related]
9. Treatment of disseminated renal cell cancer with combinations of interleukin-2, lymphokine-activated killer cells, and alpha-interferon.
Stoter G; Goey SH; Batchelor D; Eggermont AM; Lamers C; Gratama JW; Bolhuis RL
Prog Clin Biol Res; 1992; 378():225-33. PubMed ID: 1301583
[No Abstract] [Full Text] [Related]
10. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
11. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
[TBL] [Abstract][Full Text] [Related]
12. [Has interleukin 2 modified the outcome of metastatic kidney cancer?].
Négrier S; Philip T
Ann Urol (Paris); 1993; 27(2):87-9. PubMed ID: 8503657
[TBL] [Abstract][Full Text] [Related]
13. [Immunotherapy of metastatic renal cell cancer].
Manseck A; Wirth M
Urologe A; 1993 Sep; 32(5):360-73. PubMed ID: 7692655
[TBL] [Abstract][Full Text] [Related]
14. [Immunotherapeutic treatment for metastatic renal carcinoma].
Hidalgo Pardo F; Gutiérrez Sanz-Gadea C; Rebassa Llull MJ; García Bueno JM; Mus Malleu A; Losada González GP; Ozonas Moragues M
Actas Urol Esp; 1998 Jan; 22(1):29-33. PubMed ID: 9542189
[TBL] [Abstract][Full Text] [Related]
15. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
Parton M; Gore M; Eisen T
J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
[TBL] [Abstract][Full Text] [Related]
16. Metastatic renal cell cancer: interleukin-2 toxicity induced by contrast agent injection.
Abi-Aad AS; Figlin RA; Belldegrun A; deKernion JB
J Immunother (1991); 1991 Aug; 10(4):292-5. PubMed ID: 1931865
[TBL] [Abstract][Full Text] [Related]
17. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous alpha interferon treatment.
Schendel DJ; Gansbacher B
Cancer Res; 1993 Sep; 53(17):4020-5. PubMed ID: 8358731
[TBL] [Abstract][Full Text] [Related]
18. Current clinical practice of induction and maintenance immunotherapy for metastatic renal cell carcinoma.
Little B; Young M; Ho KJ
Int J Clin Pract; 2002; 56(1):36-9. PubMed ID: 11831831
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402
[TBL] [Abstract][Full Text] [Related]
20. Studies of the immunological effects of interleukin-2 in patients with bladder cancer and renal cell carcinoma.
Hermann GG
APMIS Suppl; 1993; 35():1-26. PubMed ID: 8251200
[No Abstract] [Full Text] [Related]
[Next] [New Search]
